Cardiology

ORION-8 results showed the change in LDL-C from baseline in the 3-year open-label extension was similar to the change observed during 18 months of placebo-controlled comparison.

Results of the 56-week VALOR-HCM trial provide new insight into the effects of mavacamten in patients with highly symptomatic obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.

Results of the FRAIL-AF trial at ESC Congress 2023 provide clinicians with further clarity into the effects of switching from vitamin K antagonists to NOACs in older patients with frailty and atrial fibrillation.

Less than 2 weeks after the release of their SELECT reaction podcast, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down for a special edition episode of Diabetes Dialogue to discuss STEP-HFpEF data and the implications for semaglutide 2.4 mg.

With BridgeBio Pharma Inc. expecting to complete a regulatory submission prior to the close of 2023, the 30-month results of ATTRibute-CM provide the most comprehensive overview yet of the benefit-risk profile for acoramidis in ATTR-CM.

Javed Butler, MD, discusses the overall results of the STEP-HFpEF trial, how he interprets the reduction in adjudicated heart failure events, and how the community's recent experience with SGLT2 inhibitors might inform uptake strategies for semaglutide 2.4 mg.

A secondary analysis of the DELIVER trial found dapagliflozin significantly reduced the full spectrum of worsening heart failure events, including outpatient oral diuretic intensification.

The largest trial to date, a meta-analysis, and new guideline recommendations have placed a spotlight on the role and benefit of iron supplementation in patients with heart failure and iron deficiency at ESC Congress 2023.

Citing more than half a dozen major trials in the 2 years since the release of their 2021 heart failure guidelines, the European Society of Cardiology has released a focused update to their heart failure guidance.

Results of the STEP-HFpEF trial suggest use of semaglutide 2.4 mg (Wegovy) was associated with improvements in physical symptoms and functional status relative to placebo therapy in adults with HFpEF and obesity.

The FDA Circulatory System Devices Panel has voted in favor of the benefit-risk profile of Recor Medical's RDN system in a 10-2 vote but declined to endorse Medtronic's system in a 6-7 vote.

Presented at ESC 2023, the accumulation of inactive time from childhood through young adulthood was related to heart damage, regardless of body weight and blood pressure.

Milind Desai, MD, MBA, comments on risk stratification for sudden cardiac death (SCD) in oHCM.

Cardiology experts discuss the importance of an accurate and prompt diagnosis of oHCM, as well as effectively educating the patient about the condition.

A pair of experts in the management of hypertrophic cardiomyopathy provide insight into the recent advances in management and reflect on what these advances have meant for patients.

A new analysis suggests improved self-recognition of myocardial infarction symptoms may reduce cardiogenic shock and death by prompting a rapid hospital visit.

A study of more than 15,000 individuals suggests regular physical activity may help prevent the development of atrial fibrillation, as well as the incidence of stroke and MACE.

An analysis of data from CREDENCE provides insight into the prognostic potential of a group of 4 common biomarkers for predicting cardiovascular and kidney issues in people with type 2 diabetes.

An analysis of data from a NYC-based health system indicate more than 1 in 5 people hospitalized for COVID-19 and 1 in 10 nonhospitalized COVID-19 patients went on to develop persistent hypertension 6 months later.

Trends show e-cigarette use in patients with CVD decreased from 2015 to 2019, but rebounded in 2019, potentially owing to the COVID-19 pandemic.

Michelle M. Kittleson, MD, PhD, and James Januzzi, MD, review signs that point to oHCM, highlighting family history and details on the diagnostic evaluation.

Andrew Wang, MD, outlines the epidemiology of obstructive hypertrophic cardiomyopathy (oHCM), and Milind Desai, MD, MBA, reviews the etiology of the condition.

A multi-center study in France found recreational drug use was independently associated with the occurrence of in-hospital outcomes.

A study led by Massachusetts General Hospital is offering insight into the antibody response achieved with each dose of mRNA vaccines among heart and lung transplant recipients relative to their healthy counterparts.

In this episode of Don't Miss a Beat, hosts offer a breakdown of 3 trials of note from the upcoming ESC Congress 2023 and provide context around the recent announcement of topline results from the SELECT trial.

In this episode, hosts take time to break down the implications of two, potentially paradigm-shifting news in the announcement of the addition of bexagliflozin to the Cost Plus Drugs platform and topline data from the landmark SELECT trial.

Health data from more than 50,000 adults revealed racial differences in cardiovascular mortality disappeared after adjusting for social risk factors.

A posthoc analysis of the pivotal SOLOIST-WHF trial provides insight into the effects of sotagliflozin use on risk of cardiovascular mortality and heart failure readmissions at 90 days.

Michael J. Blaha, MD, MPH, discusses his interpretation of the growing data detailing the role of inflammation as a driver of cardiovascular risk and how clinicians can identify patients who stand to benefit most from colchicine 0.5 mg tablets.

In a recent Q&A, Michael Blaha, MD, discusses how he views the ideal role of cardiologists in the management of obesity and how this role could change based on the results of the SELECT trial.